Klaria Pharma Holding AB (SE:KLAR)
:KLAR
Want to see SE:KLAR full AI Analyst Report?
KLAR Stock Chart & Stats
kr0.61
>-kr0.01(-0.40%)
At close: 4:00 PM EST
kr0.61
>-kr0.01(-0.40%)
Day’s Range― - ―
52-Week Rangekr0.39 - kr1.33
Previous CloseN/A
Volume243.47K
Average Volume (3M)401.28K
Market Cap
kr197.03M
Enterprise Valuekr270.86M
Total Cash (Recent Filing)kr342.00K
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding245,976,150
10 Day Avg. Volume684,621
30 Day Avg. Volume401,283
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr24.00M
Bulls Say, Bears Say
Bulls Say
Debt ReductionEliminating interest-bearing debt is a durable improvement to financial flexibility: it reduces fixed financing costs and lowers near-term default risk, making the company more able to prioritize R&D or partner deals without servicing lenders. However, other balance sheet weaknesses remain.
Proprietary Drug-Delivery PlatformA differentiated mucoadhesive oral film platform is a structural competitive asset: it can enable faster systemic uptake, potential IP protection, and multiple indication applications. This platform approach supports licensing and partnering, creating recurring long-term value beyond single-product risk.
Partner-Focused Commercialization StrategyPrioritizing partnerships for commercialization is a durable, capital-light model: it lets the company concentrate on development and leverage partners' sales infrastructure, lowering commercialization capex and execution risk while enabling access to broader markets without scaling a large commercial organization.
Bears Say
Negative EquityNegative shareholders' equity is a structural financial weakness that signals accumulated losses or dilution and materially reduces financial flexibility. It limits borrowing capacity, heightens scrutiny from counterparties, and increases the likelihood of dilutive recapitalizations to fund ongoing operations.
Persistent Cash BurnConsistent negative operating cash flow and a large 2025 outflow create an enduring funding requirement. Relying on external financing raises execution risk, increases dilution potential, and can force strategic concessions to partners or acquirers if cash needs intensify before value-driving clinical milestones are achieved.
Sustained Loss-Making OperationsDeep, persistent losses and extremely negative margins indicate the business has not yet achieved scalable economics. Without durable revenue generation or margin improvement, profitability risks remain high, pressuring ability to self-fund development and increasing dependence on external capital or partnerships.
KLAR FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was kr0.39 and its highest was kr1.33 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is kr197.03M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on May 29, 2026. The company reported -kr0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.035.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -kr0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.38%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:KLAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.